Login to Your Account

Clinic Roundup

Wednesday, June 13, 2012
• Cempra Inc., of Chapel Hill, N.C., dosed the first two patients in its Phase II trial evaluating the efficacy, safety and tolerability of solithromycin in uncomplicated urogenital gonococcal infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription